FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program
FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program
Two drug manufacturers, The Biden-Harris administration has announced an initiative to improve access to gene therapies for sickle cell disease under the Cell and Gene Therapy Access Model.
拜登-哈里斯政府宣布启动一项计划，旨在改善《电芯与基因疗法接触模型》下镰状细胞病的基因疗法获取途径。
This voluntary model, developed by the Center for Medicare and Medicaid Innovation, seeks to enhance access to these therapies, improve patient outcomes, and reduce healthcare costs by tying payments to treatment efficacy for Medicaid recipients.
这一自愿模型由康哲药业创新中心开发，旨在提高这些疗法的获取途径，改善患者预后，并通过将支付与治疗效果挂钩以降低医保受益者的医疗成本。
Also Read: FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy
另请阅读：FDA调查与bluebird bio的Skysona基因疗法相关的潜在危及生命的血液癌风险。
Two drug manufacturers, Bluebird Bio Inc. (NASDAQ:BLUE) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), have agreed to participate in the model with their FDA-approved therapies, Lyfgenia and Casgevy.
两家药品制造商，bluebird bio Inc.（纳斯达克：BLUE）和Vertex Pharmaceuticals Inc.（纳斯达克：VRTX），已同意参与该模型，他们的FDA批准疗法Lyfgenia和Casgevy。
CMS is working to engage states and U.S. territories enrolled in the Medicaid Drug Rebate Program, providing technical support and data infrastructure for implementation.
康哲药业正在与加入医保药品返点计划的各州和美国领土合作，提供技术支持和数据基础设施以供实施。
States may apply to participate starting this month, with applications accepted until Feb. 28, 2025.
各州可在本月开始申请参与，申请截至日期为2025年2月28日。
Over 100,000 individuals in the U.S. live with sickle cell disease, more than half of whom rely on Medicaid. The disease significantly reduces life expectancy and imposes an annual economic burden of nearly $3 billion in healthcare costs.
美国有超过10万名患有镰状细胞病的个体，其中一半以上依赖于医保。该疾病显著降低了预期寿命，并给医疗成本带来每年近30亿美元的经济负担。
The Food and Drug Administration (FDA) approved Lyfgenia and Casgevy in December 2023 as gene therapies targeting sickle cell disease.
美国食品药品监督管理局（FDA）于2023年12月批准了针对镰状细胞病的基因疗法Lyfgenia和Casgevy。
Launching in January 2025, the model allows states to join until January 2026. States can also apply for optional funding to support implementation.
该模型将于2025年1月推出，各州可以加入，直到2026年1月。各州还可以申请可选资金以支持实施。
This initiative aligns with President Biden's 2022 Executive Order to expand access to novel therapies and reduce prescription drug costs. Future expansions of the model may include other cell and gene therapies.
这一倡议与拜登总统2022年的行政命令保持一致，扩大创新疗法的获取，并降低处方药费用。该模型未来的扩展可能包括其他电芯和基因疗法。
- Ford's Mustang Mach-E Sales Skyrocket 38.3% In November Amid Growing EV Momentum
- 福特的野马Mach-E销量在11月大幅上升38.3%，伴随着不断增长的电动车动能。
Image: Shutterstock
图片：shutterstock